Weiss Law Investigates IVERIC bio, Inc.

NEW YORK, May 1, 2023 /PRNewswire/ — Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of IVERIC bio, Inc. (“IVERIC” or the “Company”) (NASDAQ: ISEE), in connection with its proposed acquisition by Astellas Pharma Inc.  Under the merger agreement, the Company’s shareholders will receive $40.00 in cash for each share of IVERIC owned.  The transaction is valued at approximately $5.9 billion.

If you own IVERIC shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/isee 
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7^th Floor
New York, NY  10007
(212) 682-3025
(888) 593-4771
[email protected]

Weiss Law is investigating whether (i) IVERIC’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $40.00 per share merger consideration adequately compensates IVERIC’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. 

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

SOURCE Weiss Law